Clinic operator NeuPath's Q3 revenue beats on fluoroscopy demand

NeuPath Health

13/11/2025 12:39

Overview

NeuPath Q3 revenue rises 26% yr/yr, beating analyst expectations

Adjusted EBITDA for Q3 up 98% yr/yr, marking 27th consecutive positive quarter

Company attributes growth to optimized clinic footprint and increased patient treatment time

Outlook

NeuPath expects continued organic and inorganic growth for the balance of 2025 and beyond

Company anticipates strong demand for Arthrosamid and increased patient visits

Result Drivers

CLINIC REVENUE - Increase driven by adjustments to physician reimbursement rates and higher demand for fluoroscopy

CAPACITY UTILIZATION - Improved to 84% in Q3, driven by revenue growth and clinic space optimization

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
C$22.10 mln
C$19.70 mln (1 Analyst)
Q3 Adjusted EBITDA
C$1.50 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for NeuPath Health Inc is C$0.50, about 27% above its November 12 closing price of C$0.37

Press Release: ID:nBwwBrWma

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)